Clinical validation of RNA sequencing for Mendelian disorder diagnostics

Sen Zhao,Kristina Macakova,Jefferson Sinson,Hongzheng dai,Jill Rosenfeld,Gladys Zapata,Shenglan Li,Patricia Ward,Christiana Wang,Chunjing Qu,Becky Maywald,Undiagnosed Diseases Network,Brendan Lee,Christine Eng,Pengfei Liu

DOI: https://doi.org/10.1101/2024.08.15.24312057

2024-08-17

Abstract:Despite rapid advancements in clinical sequencing, over half of diagnostic evaluations still lack definitive results. RNA-seq has shown promise in research settings for bridging this gap by providing essential functional data for accurate interpretation of diagnostic sequencing results. However, despite advanced research pipelines, clinical translation of diagnostic RNA-seq has not yet been realized. We have developed and validated a clinical diagnostic RNA-seq test in a CLIA laboratory for individuals with suspected genetic disorders who have existing or concurrent comprehensive DNA diagnostic testing. This diagnostic RNA-seq test processes patient RNA samples from fibroblasts or blood and derives clinical interpretations based on the analytical detection of outliers in gene expressions and splicing patterns. The clinical validation involves 150 samples, including benchmark, negative, and positive samples. We developed provisional expression and splicing benchmarks using short-read and long-read RNA-seq data from the HG002 lymphoblastoid sample produced by the Genome in a Bottle Consortium. Our validation data achieved analytical sensitivity and specificity higher than 99% against the benchmarks. For clinical validation, we first established reference ranges for each gene and junction based on expression distributions from our control data. We then evaluated the clinical performance of our outlier-based pipeline using positive samples with previously identified diagnostic findings from the Undiagnosed Diseases Network project. Our pipeline identified 19 of 20 positive findings in both fibroblast and blood samples and highlighted the limitations of the test. Our study provides a paradigm and necessary resources for independent laboratories to validate a clinical RNA-seq test.

Genetic and Genomic Medicine

What problem does this paper attempt to address?

The paper aims to address the following issues:

1. **Improving the diagnosis rate of Mendelian diseases**: Despite the rapid advancement of clinical sequencing technologies, more than half of diagnostic evaluations still lack definitive results. RNA sequencing (RNA-seq) has shown potential in research settings to fill this gap by providing crucial functional data to accurately interpret diagnostic sequencing results.

2. **Achieving clinical translation of RNA-seq**: Although advanced research workflows exist, the clinical application of RNA-seq has not yet been realized. This paper develops and validates a clinical diagnostic RNA-seq testing method for individuals with suspected genetic diseases who have already undergone or are undergoing comprehensive DNA diagnostic testing.

3. **Establishing reliable reference ranges and standards**: To ensure the accuracy and reliability of RNA-seq testing, researchers need to establish reference ranges for gene expression and splicing sites and generate control data to distinguish diagnostic outliers from background noise. This paper uses public resources (such as data from the Genome in a Bottle Consortium) to establish preliminary expression and splicing benchmarks.

4. **Evaluating clinical performance**: Researchers evaluated the clinical performance of the RNA-seq test using samples with previously known diagnostic results, particularly detecting 19 out of 19 positive results from fibroblast and blood samples, highlighting the test's limitations.

In summary, this paper aims to improve the accuracy of Mendelian disease diagnosis by developing and validating a new RNA-seq testing method and providing the necessary resources for independent laboratories to validate clinical RNA-seq tests.